These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19925830)

  • 21. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
    Cihlar T; Ray AS
    Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV integrase as a target for antiviral chemotherapy.
    Nair V
    Rev Med Virol; 2002; 12(3):179-93. PubMed ID: 11987143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular basis of human immunodeficiency virus drug resistance: an update.
    Menéndez-Arias L
    Antiviral Res; 2010 Jan; 85(1):210-31. PubMed ID: 19616029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.
    Dickinson L; Khoo S; Back D
    Antiviral Res; 2010 Jan; 85(1):176-89. PubMed ID: 19665485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV drug resistance against strand transfer integrase inhibitors.
    Anstett K; Brenner B; Mesplede T; Wainberg MA
    Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
    Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
    J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.
    Wensing AM; van Maarseveen NM; Nijhuis M
    Antiviral Res; 2010 Jan; 85(1):59-74. PubMed ID: 19853627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 integrase inhibitors: a review of their chemical development.
    Ingale KB; Bhatia MS
    Antivir Chem Chemother; 2011 Nov; 22(3):95-105. PubMed ID: 22095518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics.
    Young SD
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):402-10. PubMed ID: 11727305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In search of a selective therapy of viral infections.
    De Clercq E
    Antiviral Res; 2010 Jan; 85(1):19-24. PubMed ID: 19852983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides.
    Martin JC; Hitchcock MJ; De Clercq E; Prusoff WH
    Antiviral Res; 2010 Jan; 85(1):34-8. PubMed ID: 19854224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.
    Park TE; Mohamed A; Kalabalik J; Sharma R
    Expert Rev Anti Infect Ther; 2015; 13(10):1195-212. PubMed ID: 26293294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
    Pendri A; Meanwell NA; Peese KM; Walker MA
    Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of HIV integrase resistance mutations.
    Quashie PK; Mesplède T; Wainberg MA
    Curr Opin Infect Dis; 2013 Feb; 26(1):43-9. PubMed ID: 23242340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.